Third Harmonic Q3 2024 Earnings Report
Key Takeaways
Third Harmonic Bio reported a net loss of $13.8 million for the third quarter of 2024, with cash and cash equivalents totaling $296.1 million as of September 30, 2024.
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25.
Cash and cash equivalents totaled $296.1 million as of September 30, 2024.
R&D expenses increased to $11.3 million for the three months ended September 30, 2024, from $6.0 million for the same period in 2023.
Net loss for the three months ended September 30, 2024, increased to $13.8 million from a net loss of $7.3 million for the same period in 2023.
Third Harmonic
Third Harmonic
Forward Guidance
Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.